Cancers: Immune-related thyroiditis is a predictor of survival in patients with metastatic kidney cancer

Background: The broad integration of immunotherapy has revolutionized cancer treatment while introducing a distinct class of immune-related adverse events (IrAEs)
.

Checkpoint inhibitors (CPIs) have been routinely used in the treatment of metastatic renal cell carcinoma (MRCC) since 2015, initially as a follow-up series of monotherapy and currently in a first-line setting, as a combination with vascular endothelial growth factor inhibitors (VEGFi) or part of a second CPI (nivolumab and ipilimumab) combination therapy

The broad integration of immunotherapy has revolutionized cancer treatment while introducing a distinct class of immune-related adverse events (IrAEs)

Methods: A retrospective cohort study of 123 consecutive patients with renal cell carcinoma treated with CPI at the same center between 2015 and 2020 was conducted
.

Disease risk stratification was assessed by two methods: the Heng criteria and a new dichotomous stratification system, 'low risk' and 'high risk' plus the number of metastatic sites

Results: IRT occurred in 38% of patients
.

In the general cohort, IRT was not associated with a survival benefit

Figure 1
.

Association of IRT with survival in all patients and Heng risk group

Figure 1

Figure 2.
IRT versus survival probability for new risk groups
.

Kaplan-Meier's Total Survival Plot

Figure 2.

Table 1.
Prevalence of Immune-Related Adverse Events in the Study Population and High-Risk Populations and Their Impact on Survival

Table 1.
Prevalence of Immune-Related Adverse Events in the Study Population and High-Risk Populations and Their Impact on Survival

CONCLUSIONS: IRT is an early and prevalent IRAE associated with prolonged survival in poor/'high-risk' renal cancer patients
.

IRT is an early and common IRAE associated with prolonged survival in patients with poor/'high-risk' kidney cancer
.

Original source: Sagie S, Gadot M, Levartovsky M, et al.

Immune-Related Thyroiditis as a Predictor for Survival in Metastatic Renal Cell Carcinoma.
Leave a Comment here